As previously announced, the 1-for-33 reverse stock split will automatically convert thirty-three current shares of TransCode’s common stock into one new share of common stock. No fractional shares ...
TransCode Therapeutics ( (RNAZ) ) has provided an update.
Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's ...
TransCode Therapeutics (RNAZ) has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8M before ...
(RTTNews) - TransCode Therapeutics, Inc. (RNAZ), a clinical-stage oncology company focused on RNA therapeutics, announced on Wednesday that it has entered into a securities purchase agreement to ...
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced ...
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company: Dear Shareholders ...
Board of Directors has approved a 1-for-33 reverse stock split. The reverse stock split was approved by TransCode’s ...
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating ...
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback